Advertisement
New Zealand markets close in 6 hours 25 minutes
  • NZX 50

    11,785.69
    -50.35 (-0.43%)
     
  • NZD/USD

    0.5905
    -0.0014 (-0.24%)
     
  • ALL ORDS

    7,898.90
    +37.90 (+0.48%)
     
  • OIL

    82.65
    -0.08 (-0.10%)
     
  • GOLD

    2,395.00
    -3.00 (-0.13%)
     

How Jazz Pharmaceuticals’ Products Performed in the Second Quarter

How Jazz Pharmaceuticals’ Products Performed in the Second Quarter

How Did Jazz Pharmaceuticals Fare in the Second Quarter? Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $356.0 million in the second quarter of 2018, which reflected ~19% year-over-year growth and ~12% sequential growth. Jazz Pharmaceuticals anticipates Xyrem’s net revenues in fiscal 2018 to be in the range of $1.87 million and $1.91 million.